Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2025
Potential for application of direct thrombin inhibitors isolated from Euphorbia resinifera O.Berg latex in fibrin clot formation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Siritapetawee Jaruwan, Hua Yanling, Talabnin Chutima, Naewwan Nopporn, Charoenwattanasatien Ratana, Phoovasawat Chalermluck, Srichan Supawan, Kantachot Chortip
Аннотация
Direct thrombin inhibitors (designated as EuRL-DTIs) were partially purified from ethanol extracts of Euphorbia resinifera O.Berg latex. The obtained EuRL-DTIs comprised four major compounds: two isomers of phenolic compounds (C19H26O12) and two amide compounds (tentatively identified as C24H44N4O4 and C36H66N6O6), as identified by liquid chromatography and electrospray ionisation quadrupole time-of-flight mass spectrometry (LC-ESI-QTOF-MS/MS), attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy, and/or nuclear magnetic resonance (NMR) spectroscopy. The effects of EuRL-DTIs on human thrombin-induced fibrin clot production were analysed using thrombin time, sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), synchrotron radiation X-ray tomographic microscopy (SRXTM), and scanning electron microscopy (SEM). Kinetic studies revealed that EuRL-DTIs inhibited human thrombin from cleaving the chromogenic substrate S2238, with a Ki of 3.7 μg/mL, in a non-competitive inhibition manner. All results supported the hypothesis that the EuRL-DTIs directly abolished thrombin activity in the production of fibrin clots without requiring a cofactor. The cytotoxicity test showed that EuRL-DTIs were nontoxic to normal human foetal lung fibroblasts (IMR-90). Thus, EuRL-DTIs have potential as antithrombotic agents for application as drugs for thrombosis treatments or in medical devices such as coating surgical sutures.